

community who will help shape the field's future by providing funding support, strategic industry guidance, and collaborative knowledge sharing. Finally, to ensure effectiveness, SNMMI is conducting ongoing evaluations of what is working and where strategies and resources need to shift.

I sincerely thank the Value Initiative domain chairs and all those working with them for accomplishments to date and ongoing efforts!

This year we also formed 2 new committees. The first, under the Therapy Center of Excellence, is the Committee on Training and Education for Competence in Radionuclide Therapy. Its members are working on a guidance document that will be sent to the Nuclear Regulatory Commission's Advisory Committee on the Medical Uses of Isotopes this summer.

The second new committee tackles a long-standing controversial issue. It will evaluate the evidence for and against the linear no-threshold hypothesis on risks of low-level radiation exposure. This is a collaborative endeavor. So far, we are working with representatives of the American Association of Physicists in Medicine, American Society for Radiation Oncology, and the Health Physics Society.

During the past year, it was a special joy to meet and work with colleagues around the globe on common issues to advance our field. In October 2017, I attended the Asia Oceania Congress of Nuclear Medicine and Biology in Yokohama, Japan, and signed a 3-year memorandum of understanding (MOU) between SNMMI and the Japanese Society of Nuclear Medicine. That same month, I attended

the EANM annual meeting in Vienna, Austria, and signed an MOU with the EANM. I also signed an MOU with the International Atomic Energy Agency for collaboration on projects, including educational activities and quality measures. More recently, I attended a meeting in Martinique, where SNMMI, EANM, the European Thyroid Association, and the American Thyroid Association met to address collaborating on issues related to the care of patients with thyroid cancer, with particular focus on radioactive iodine therapy.

It has truly been a privilege to serve SNMMI as president. I extend a warm thank you to all who have volunteered and helped advance the many initiatives of the society! In particular, I would like to thank Satoshi Minoshima, MD, PhD; Vasken Dilsizian, MD; Sally Schwarz, MS; and Virginia Pappas, CAE, in the SNMMI leadership team for providing valuable advice during my term. It has also been a great pleasure to work with Michael Middleton, MD; Katherine Zukotynski, MD; Kathy Krisak, BS, CNMT; and Norman Bolus, MSPH, CNMT, in the executive team. My thanks also go to the SNMMI Board of Directors and the staff for their assistance. And last, but certainly not least, my sincere thanks to my wife for her understanding and support.

As I now turn the leadership over to Dr. Minoshima, I am optimistic about a future in which molecular imaging and diagnostic and therapeutic nuclear medicine are fully recognized for their roles in providing high quality, precision care, and improving patients' lives.

Aria Razmaria, MD, Awarded 2018 Henkin Fellowship


SNMMI and the Education and Research Foundation for Nuclear Medicine and Molecular Imaging announced on April 11 that Aria Razmaria, MD, is the recipient of the 2018 Robert E. Henkin Government Relations Fellowship. Each year, fellowship recipients travel to Washington, DC, and spend a week with SNMMI staff, visiting Congress, federal agencies, and other medical societies. Throughout the visit, fellows learn about ways in which federal legislative and regulatory processes affect nuclear medicine and molecular imaging. The program is designed for young professionals, defined as residents or fellows (physicians, scientists, or technologists) who have completed training within the last 10 years.

Dr. Razmaria is a graduate of the Medical University of Vienna (Austria). After completion of training in family medicine and urology, he spent several years in clinical research at the University of Chicago (IL), focusing on prostate cancer treatment outcomes. He is pursuing his training in nuclear medicine at the University of California

Los Angeles Medical Center and the Greater Los Angeles Veterans Affairs Healthcare System. He has presented his research at national and international venues and has authored more than 35 peer-reviewed publications and book chapters. He currently serves on the board of directors of the Nuclear Medicine Resident/Fellow Organization (NMRO), is the nuclear medicine resident delegate to the American Medical Association, and is the editor of the NMRO

newsletter *Scintillator*. Dr. Razmaria's research interests are in innovative targeted molecular imaging and therapeutic agents for prostate cancer. He is also engaged in advocacy and public representation of the field of nuclear medicine.

This fellowship was made possible by contributions from Robert E. Henkin, MD.



Aria Razmaria, MD